Nippon Shinyaku Co., Ltd. And Innovive Pharmaceuticals, Inc. Conclude Licensing Agreement For NS-187, Drug Candidate For Chronic Myelogenous Leukemia

Published: Jan 06, 2006

Tokyo (JCN) Jan 6, 2006 - Nippon Shinyaku announced on January 5 that it concluded a licensing agreement with INNOVIVE Pharmaceuticals of New York on December 28, 2005. Under the agreement terms, INNOVIVE Pharmaceuticals will be licensed to exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan.

Back to news